Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PainChek Ltd ( (AU:PCK) ) has provided an update.
PainChek Ltd has received a De Novo classification from the FDA for its PainChek Adult App, marking it as the first regulated medical device for pain assessment in the US. This approval opens up a significant market opportunity in the US aged care sector, estimated at over USD $100 million annually, and positions the company for rapid expansion into other segments like home care and hospitals. Strategic partnerships with major healthcare software providers and a strong regulatory landscape further enhance PainChek’s market entry and growth prospects in the US and globally.
More about PainChek Ltd
PainChek Ltd is a company that develops smart device-based applications for pain assessment and monitoring. It operates in the healthcare industry, focusing on providing innovative solutions for pain management, particularly in aged care markets. The company is known for its PainChek Adult App, which is the first regulated medical device of its kind for pain assessment.
Average Trading Volume: 2,783,976
Technical Sentiment Signal: Buy
Current Market Cap: A$165.1M
See more data about PCK stock on TipRanks’ Stock Analysis page.